These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31742861)

  • 1. TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL-2R signalling pathway.
    Zhu M; Yang L; Shi X; Gong Z; Yu R; Zhang D; Zhang Y; Ma W
    J Cell Mol Med; 2020 Jan; 24(1):984-995. PubMed ID: 31742861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel biphenyl urea derivate inhibits the invasion of breast cancer through the modulation of CXCR4.
    Zhan Y; Zhang H; Li J; Zhang Y; Zhang J; He L
    J Cell Mol Med; 2015 Jul; 19(7):1614-23. PubMed ID: 25753200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel biphenyl urea compound, TPD7, stimulates apoptosis through modulating Fas signaling and Bcl-2 family proteins in cervical cancer.
    Zhan Y; Zhang H; Dai B; Zhang Y; Zhang J; He L
    Oncol Rep; 2018 Aug; 40(2):1064-1072. PubMed ID: 29901176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Effect of TPD7 and Berberine against Leukemia Jurkat Cell Growth through Regulating Ephrin-B2 Signaling.
    Ma W; Zhu M; Yang L; Yang T; Zhang Y
    Phytother Res; 2017 Sep; 31(9):1392-1399. PubMed ID: 28703366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
    Wozniak MB; Villuendas R; Bischoff JR; Aparicio CB; Martínez Leal JF; de La Cueva P; Rodriguez ME; Herreros B; Martin-Perez D; Longo MI; Herrera M; Piris MA; Ortiz-Romero PL
    Haematologica; 2010 Apr; 95(4):613-21. PubMed ID: 20133897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
    Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
    Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
    Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP.
    Sumarni U; Reidel U; Eberle J
    Cells; 2021 Apr; 10(5):. PubMed ID: 33922439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TPD7 inhibits the non-small cell lung cancer HCC827 cell growth by regulating EGFR signalling pathway.
    Zhang X; Zhang H; Qi G; Gu X; Zhao Y; Zhang J
    J Chemother; 2022 Apr; 34(2):110-116. PubMed ID: 34210250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ND-16: A Novel Compound for Inhibiting the Growth of Cutaneous T Cell Lymphoma by Targeting JAK2.
    Zhu M; Liu Y; Lei P; Shi X; Tang W; Huang X; Pan X; Wang C; Ma W
    Curr Cancer Drug Targets; 2022; 22(4):328-339. PubMed ID: 35220934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
    Chang TP; Poltoratsky V; Vancurova I
    J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis.
    Abdulrahman N; Leo R; Boumenar HA; Ahmad F; Mateo JM; Jochebeth A; Al-Sowaidi NK; Sher G; Ansari AW; Alam M; Uddin S; Ahmad A; Steinhoff M; Buddenkotte J
    Leuk Lymphoma; 2023 Dec; 64(14):2236-2248. PubMed ID: 37708450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The retinoid derivant ECPIRM selectively exhibited anti-proliferation effects in cutaneous T-Cell lymphoma via ITK-mediated signaling pathway.
    Li H; Wang C; Ma P; Zhang M; Yang H; Yuan S; Wei J; Tao L; Qian K; Xu M; Li L
    J Dermatol Sci; 2020 Mar; 97(3):208-215. PubMed ID: 32165081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
    Wang Y; Gu X; Li W; Zhang Q; Zhang C
    J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
    Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
    Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
    Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
    Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
    Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
    Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells.
    Qin JZ; Zhang CL; Kamarashev J; Dummer R; Burg G; Döbbeling U
    Blood; 2001 Nov; 98(9):2778-83. PubMed ID: 11675351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
    Zhang Q; Nowak I; Vonderheid EC; Rook AH; Kadin ME; Nowell PC; Shaw LM; Wasik MA
    Proc Natl Acad Sci U S A; 1996 Aug; 93(17):9148-53. PubMed ID: 8799169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.